ST. LOUIS, Jan. 27 /PRNewswire/ -- Notal Vision's ForeseeHome™ AMD Monitor has received Section 510 (k) clearance from the U.S. Food and Drug Administration (FDA).
The ForeseeHome AMD Monitor is the first ophthalmic device linking patients and doctors between eye exams for ongoing monitoring of age-related macular degeneration (AMD). Patients complete a frequent but brief exam on their ForeseeHome AMD Monitor, in the comfort of their own home, and data is transmitted to the patients' eye care physician and the Notal Vision Data Monitoring Center. The award winning ergonomic design of the ForeseeHome AMD Monitor is comfortable and easy to use for patients at risk of vision loss from wet AMD.
Wet AMD is the leading cause of blindness in people over the age of 60 in the western world. Recent breakthroughs in treatments place even greater importance on early detection, which can reduce the risks of vision loss associated with wet AMD. Frequent monitoring is critical in detecting disease onset as early as possible and the ForeseeHome AMD Monitor is the first home monitoring device for following patients at risk of vision loss, offering hope for early intervention through early detection.
Numerous clinical studies have demonstrated the ForeseeHome AMD Monitor is an accurate and reliable tool for frequent monitoring of patients at risk for vision loss from wet AMD.
For more information, please visit www.notalvision.com.
Notal Vision was founded by a team of medical professionals determined to develop better methods of AMD monitoring and reduce vision loss associated with AMD. Notal Vision's corporate headquarters are located in Tel Aviv, Israel, with U.S. headquarters and a distribution center in St. Louis, MO.
SOURCE Notal Vision
|SOURCE Notal Vision|
Copyright©2010 PR Newswire.
All rights reserved